Hypha Labs, Inc.
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Hypha Labs, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Hypha Labs, Inc. - Asset Resilience Ratio
Hypha Labs, Inc. (FUNI) has an Asset Resilience Ratio of 1.76% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2021)
This chart shows how Hypha Labs, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hypha Labs, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.70K | 1.76% |
| Total Liquid Assets | $20.70K | 1.76% |
Asset Resilience Insights
- Limited Liquidity: Hypha Labs, Inc. maintains only 1.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hypha Labs, Inc. Industry Peers by Asset Resilience Ratio
Compare Hypha Labs, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 14.36% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Hypha Labs, Inc. (2014–2021)
The table below shows the annual Asset Resilience Ratio data for Hypha Labs, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-09-30 | 1.31% | $24.75K | $1.89 Million | +0.27pp |
| 2020-09-30 | 1.04% | $18.68K | $1.79 Million | -2.77pp |
| 2019-09-30 | 3.81% | $51.70K | $1.36 Million | +1.98pp |
| 2018-09-30 | 1.83% | $25.65K | $1.40 Million | +0.20pp |
| 2017-09-30 | 1.63% | $25.65K | $1.57 Million | +1.00pp |
| 2014-09-30 | 0.63% | $36.03K | $5.68 Million | -- |